脊髓性肌肉萎缩症市场，按类型、治疗、年龄层、给药途径、配销通路和地区 - 规模、份额、前景和机会分析，2024 年至 2031 年

预计到 2024 年，全球脊髓性肌肉萎缩症市场价值将达到 20.135 亿美元，预计在预测期内（2024-2031 年）复合年增长率为 13.3%。

2024 年全球脊髓性肌肉萎缩症市场价值（百万美元），按地区划分

脊髓性肌肉萎缩症 (SMA) 是一种影响週边神经系统、中枢神经系统和随意肌肉运动（骨骼肌）的遗传性疾病。 SMA 是肌肉性的，因为它主要影响肌肉，而肌肉不会接收来自神经细胞的脉衝。萎缩是收缩的医学术语，这是肌肉在不受神经细胞刺激时所做的事情。 SMA 是一种运动神经元疾病，包括脊髓中称为运动神经元的神经细胞的损失。它主要影响婴儿和儿童，但也可能发生在成人中。患有 SMA 的个体继承了两个有缺陷（突变）或缺失的运动神经元存活基因 1 (SMN1) 基因。

市场动态

市场主要参与者不断推出的产品预计将在预测期内推动市场成长。例如，2021年8月，日本药品製造商中外製药株式会社宣布推出Evrysdi干糖浆60毫克（通用名：risdiplam），用于治疗脊髓性肌肉萎缩症（SMA）。

此外，主要参与者越来越多地采用无机策略，例如伙伴关係和协作，预计将在预测期内推动市场成长。例如，2021 年 3 月，全球 SMA 研究的主要资助者脊髓性肌肉萎缩症基金会与美国製药公司 PTC Therapeutics, Inc. 达成新的合作，专注于开发新疗法和再生医学，以进一步推进SMA 和其他神经肌肉疾病的科学研究。

研究的主要特点：

• 该报告对全球脊髓性肌肉萎缩症市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。
• 它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
• 这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
• 它根据以下参数介绍了全球脊髓性肌肉萎缩症市场的主要参与者 - 公司亮点、产品组合、主要亮点、财务表现和策略。
• 该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球脊髓性肌肉萎缩症市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师1。
• 利害关係人可以透过用于分析全球脊髓性肌肉萎缩症市场的各种策略矩阵轻鬆做出决策。

目录

第一章：研究目标与假设

• 研究目标
• 假设
• 缩写

第 2 章：市场范围

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map (COM)

第 3 章：市场动态、法规与趋势分析

• 市场动态
  • 司机
  • 限制
  • 市场机会
• 影响分析
• 市场走向
• 收购和合作场景
• 技术进步
• 监管场景
• PEST分析
• 产品发布

第 4 章：全球脊髓性肌肉萎缩症市场 - 冠状病毒 (Covid-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第 5 章：2019 - 2031 年全球脊髓性肌肉萎缩症市场（按类型）

• 概述
• Ⅰ型
• II型
• Ⅲ型
• 四型

第 6 章：2019 - 2031 年全球脊髓性肌肉萎缩症市场（依治疗）

• 概述
• 基因治疗
• 疾病缓解药物

第 7 章：全球脊髓性肌肉萎缩症市场，依年龄划分，2019 - 2031 年

• 概述
• 婴儿
• 成人

第 8 章：2019 - 2031 年全球脊髓性肌肉萎缩症市场（依给药途径）

• 概述
• 口服
• 注射剂

第 9 章：全球脊髓性肌肉萎缩症市场，依配销通路，2019 - 2031 年

• 概述
• 医院药房
• 零售药局
• 网路药局

第 10 章：2019 - 2031 年全球脊髓性肌肉萎缩症市场（按地区）

• 介绍
• 北美洲
• 我们
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地区
• 欧洲
• 英国
• 德国
• 义大利
• 法国
• 西班牙
• 俄罗斯
• 欧洲其他地区
• 亚太地区
• 中国
• 印度
• 日本
• 东协
• 澳洲
• 韩国
• 亚太地区其他地区
• 中东
• 海湾合作委员会
• 以色列
• 中东其他地区
• 非洲
• 北非
• 中非
• 南非

第 11 章：竞争格局

• Biogen
• CYTOKINETICS
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• PTC Therapeutics, Inc.
• Novartis AG
• Ionis Pharmaceuticals
• Chugai Pharmaceutical Co., Ltd.
• NMD PHARMA A/S
• Astellas Pharma Inc.

第 12 章：分析师建议

• 命运之轮
• 分析师观点
• 连贯的机会图

第 13 章：部分

• 参考
• 研究方法论

Global spinal muscular atrophy market is estimated to be valued at USD 2,013.5 Mn in 2024 and is expected to exhibit a CAGR of 13.3% during the forecast period (2024-2031).

Global Spinal Muscular Atrophy Market Value (US$ Mn), by Region, 2024

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study:

• This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Detailed Segmentation:

• Global Spinal Muscular Atrophy Market, By Type:
  • Type I
  • Type II
  • Type III
  • Type IV
• Global Spinal Muscular Atrophy Market, By Treatment:
  • Gene Therapy
  • Disease-modifying drugs
• Global Spinal Muscular Atrophy Market, By Age Group:
  • Infant
  • Adult
• Global Spinal Muscular Atrophy Market, By Route of Administration:
  • Oral
  • Injectables
• Global Spinal Muscular Atrophy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Spinal Muscular Atrophy Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
• Company Profiles
  • Biogen
  • CYTOKINETICS
  • Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment
  • Market Snapshot, By Age
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Acquisitions and Partnerships Scenario
• Technological Advancements
• Regulatory Scenario
• PEST Analysis
• Product Launches

4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Spinal Muscular Atrophy Market, By Type, 2019 - 2031, (US$ Million)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Type I
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Type II
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Type III
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Type IV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

6. Global Spinal Muscular Atrophy Market, By Treatment, 2019 - 2031, (US$ Million)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Gene Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Disease-modifying drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

7. Global Spinal Muscular Atrophy Market, By Age, 2019 - 2031, (US$ Million)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Infant
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Adult
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2019 - 2031, (US$ Million)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Injectables
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2019 - 2031, (US$ Million)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

10. Global Spinal Muscular Atrophy Market, By Region, 2019 - 2031, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (US$ Million)
• North Africa
• Central Africa
• South Africa

11. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CYTOKINETICS
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• PTC Therapeutics, Inc.
• Novartis AG
• Ionis Pharmaceuticals
• Chugai Pharmaceutical Co., Ltd.
• NMD PHARMA A/S
• Astellas Pharma Inc.

12. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. Section

• References
• Research Methodology
• About Us and Sales Contact